RxDoctor Payments Data

Eric Pacini, MD

Cardiovascular Disease · Portland, ORNPI 1043420086

Payments from drug & device makers

$1,020in general payments, 2019–2025

Across 46 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$228
  • Novartis$180
  • Boston Scientific$110
  • Amgen$101
  • Kiniksa Pharmaceuticals International, PLC$74
  • E.r. Squibb & Sons, L.L.C.$63
  • plus $263 from 11 others

What the payments were for

  • Food & beverage$90989%
  • Education$11111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,020 in reported general payments places this provider in the 45th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$107,095
Medicare patients
984
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$117,162
FarxigaDapagliflozin Propanediol58$47,252
EntrestoSacubitril/Valsartan43$45,369
JardianceEmpagliflozin22$19,015
Repatha SureclickEvolocumab19$16,628
XareltoRivaroxaban17$15,031
Metoprolol Succinate270$3,360
Torsemide19$946
Carvedilol92$820
Rosuvastatin Calcium43$815
Atorvastatin Calcium76$742
Lisinopril43$719
Spironolactone81$693
Losartan Potassium95$687
Amlodipine Besylate91$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$228$47,25258 claims
NovartisEntresto$180$45,36943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →